DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects

TLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Yosuke, Nagai, Yasuhiro, Hirose, Yuko, Hori, Seiji, Koga-Yamakawa, Erina, Eguchi, Ken, Sumida, Kentaro, Murata, Masashi, Umehara, Hiroki, Yamamoto, Setsuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922899/
https://www.ncbi.nlm.nih.gov/pubmed/36793737
http://dx.doi.org/10.3389/fimmu.2023.1055671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922899/
https://www.ncbi.nlm.nih.gov/pubmed/36793737
http://dx.doi.org/10.3389/fimmu.2023.1055671

Ejemplares similares